BioWorld Asia

May 18, 2005

NovImmune, Serono Enter Antibody Deal Worth $122M

NovImmune SA entered its first product out-licensing pact, a deal with Serono SA, which is potentially worth up to $122 million for two preclinical fully human antibodies, NI-0401 and NI-0501. (BioWorld International) Read More

To Increase Pipeline, CAT Pushing Back Profitability

Positive Results At ASCO For Nicotine Vaccine Raise Hopes

AC Immune Gets CHF21M For Sensitive Antibodie

Initiatives Aim To Make UK Top Spot For Clinical Trials

Intec Pharma Gets New CEO, Plans 'Accordion Pill' Program

Law On Agricultural Biotech Stuck In German Parliament

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...